Just looking back at Quarterly Report from January this year :...

Just looking back at Quarterly Report from January this year :

One section in particular :

"Point of care – the core ability of Mix&Go is to deliver the greatest value propositions in nano situations, where surface areas are miniaturised and traditionally difficult to work with. The ability to provide all of device value propositions in POC is profound. The AMG200nm kit was the first commercial product delivered to the POC market and continues to be at the forefront of commercial interactions. It forms an important component in a new tropical disease assay currently going through regulatory approval."

Also reading the Annual Report from last year from the first introduction paragraph :

"This growth in the IVD subsector, which was estimated to be worth $50 billion in 2012, is being driven by a number of macro factors, including a burgeoning ageing population; the push to deliver test results sooner, more accurately, and cheaper; increased capacity in emerging markets to pay for tests which were previously cost-prohibitive (such as India, where more than 100 million malarial tests are now run per year), as well as the trend towards a Point of Care testing model that allows patients to be tested at home or in medical practices, rather than in hospitals. Additionally, there is a trend towards miniaturisation driven by a desire to use less blood"

This below was from the quarterly July 2015 :

"Collaborative work has also resulted in a supply agreement for use of the AMG coupling kit 200nm in Point of Care (POC) products"